- Home
- AMGN vs BX Comparison
AMGN vs BX Comparison
Compare AMGN & BX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- BX
- Stock Information
- Founded
- AMGN 1980
- BX 1985
- Country
- AMGN United States
- BX United States
- Employees
- AMGN N/A
- BX N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- BX Investment Managers
- Sector
- AMGN Health Care
- BX Finance
- Exchange
- AMGN Nasdaq
- BX Nasdaq
- Market Cap
- AMGN 156.2B
- BX 130.9B
- IPO Year
- AMGN N/A
- BX 2007
- Fundamental
- Price
- AMGN $303.01
- BX $158.35
- Analyst Decision
- AMGN Buy
- BX Buy
- Analyst Count
- AMGN 21
- BX 16
- Target Price
- AMGN $322.26
- BX $173.60
- AVG Volume (30 Days)
- AMGN 3.1M
- BX 3.6M
- Earning Date
- AMGN 02-04-2025
- BX 04-17-2025
- Dividend Yield
- AMGN 3.14%
- BX 2.49%
- EPS Growth
- AMGN N/A
- BX 96.74
- EPS
- AMGN 7.56
- BX 3.62
- Revenue
- AMGN $33,424,000,000.00
- BX $12,662,587,000.00
- Revenue This Year
- AMGN $5.39
- BX $13.59
- Revenue Next Year
- AMGN $1.55
- BX $20.86
- P/E Ratio
- AMGN $40.08
- BX $43.75
- Revenue Growth
- AMGN 18.57
- BX 64.79
- 52 Week Low
- AMGN $253.30
- BX $115.82
- 52 Week High
- AMGN $346.85
- BX $200.96
- Technical
- Relative Strength Index (RSI)
- AMGN 65.77
- BX 33.34
- Support Level
- AMGN $289.00
- BX $158.46
- Resistance Level
- AMGN $298.35
- BX $167.98
- Average True Range (ATR)
- AMGN 7.14
- BX 5.03
- MACD
- AMGN 0.17
- BX -1.02
- Stochastic Oscillator
- AMGN 75.16
- BX 3.04
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About BX Blackstone Inc.
Blackstone is the world's largest alternative-asset manager with $1.108 trillion in total asset under management, including $820.5 billion in fee-earning assets under management, at the end of September 2024. The company has four core business segments: private equity (25% of fee-earning AUM and 30% of base management fees), real estate (35% and 39%), credit and insurance (31% and 24%), and multi-asset investing (9% and 7%). While the firm primarily serves institutional investors (87% of AUM), it also caters to clients in the high-net-worth channel (13%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).